References: ZOMETA® Dosing For Tumour-Induced Hypercalcaemia (TIH)
Home


About ZOMETA

ZOMETA Patient Case Studies

Zometa Dosing & Administration
Dosing for bone metastases
Dosing for TIH

ZOMETA Safety & Tolerability

ZOMETA Clinical News

ZOMETA For Your Patients

Professional Resource Center

ZOMETA Around the World
Videos
View videos on bone
metastases and the ZOMETA
mechanism of action

Learn more about the ZOMETA(zoledronic acid) mechanism of action

 
European Summary of Product Characteristics
For non-U.S. Healthcare Professionals: Get information about ZOMETA and its product characteristics

Learn more about ZOMETA product characteristics
 
Zometa Dosing & Administration: Dosing for TIH ZOMETA is the current standard of care for the prevention of skeletal-related events (SREs)


4mg dosing hydration strategies ensuring renal safety references

References: 1. ZOMETA® Summary of Product Characteristics. Novartis Pharma AG. 2. Major P. The use of zoledronic acid, a novel, highly potent bisphosphonate, for the treatment of hypercalcemia of malignancy.Oncologist. 2002;7:481-491. 3. ZOMETA US Prescribing Information. Novartis Pharmaceuticals Corporation.